Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Harnessing Human Stem Cells for the Treatment of Glioblastoma – Twenty Year Perspective – Review of Preclinical and Clinical Studies: 2000–2020

Version 1 : Received: 26 October 2020 / Approved: 29 October 2020 / Online: 29 October 2020 (15:51:04 CET)

How to cite: Calinescu, A.; Kauss, M.C.; Sultan, Z.; Al-Holou, W.N.; O'Shea, S.K. Harnessing Human Stem Cells for the Treatment of Glioblastoma – Twenty Year Perspective – Review of Preclinical and Clinical Studies: 2000–2020. Preprints 2020, 2020100623 (doi: 10.20944/preprints202010.0623.v1). Calinescu, A.; Kauss, M.C.; Sultan, Z.; Al-Holou, W.N.; O'Shea, S.K. Harnessing Human Stem Cells for the Treatment of Glioblastoma – Twenty Year Perspective – Review of Preclinical and Clinical Studies: 2000–2020. Preprints 2020, 2020100623 (doi: 10.20944/preprints202010.0623.v1).

Abstract

The potential of Neural Stem Cells (NSCs) to provide therapeutic benefit for a variety of neurological disorders, including brain malignancies, has been long recognized and has inspired many scientists to design, test and successfully demonstrate that NSCs are efficient and effective therapeutic agents. Glioblastoma, the deadliest form of primary brain tumor, despite extensive and sustained efforts to find better therapies, remains a disease without cure, with a median survival after diagnosis of less than two years. Treatment resistance in glioblastoma is in large part attributed to limitations in the delivery and distribution of therapeutic agents administered either systemically or directly into the tumor due to the highly invasive nature of this cancer and its abnormal intratumoral vasculature. Stem Cells (SCs) have an innate tumor-tropic migratory behavior, can be modified to deliver a variety of therapeutic agents and efficiently distribute their cargo into brain tumors, pursuing invading streams of tumor cells, deep into the brain parenchyma. Over the last twenty years, numerous preclinical trials have demonstrated the feasibility and efficacy of SCs as antiglioma agents, leading to the development of trials to test these therapies in the clinic. In this review we present and analyze these studies and discuss mechanisms underlying their beneficial effect, highlighting experimental progress, limitations and the emergence of promising new therapeutic avenues. We hope to increase awareness of the advantages of using SCs for the treatment of glioblastoma and inspire further studies that will lead to accelerated implementation of effective therapies.

Subject Areas

Glioblastoma; Neural Stem Cells; Mesenchymal Stem Cells; Stem Cell Therapy; Enzyme/Prodrug Therapy; Oncolytic Virotherapy; Nanoparticles; TRAIL; Cytokine Therapy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.